Phase III clinical trial of L-105 in patients with hepatic encephalopathy

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222041

Enrollment

180

Registered

2013-03-14

Start date

2013-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H.E.

Interventions

investigational material(s) Generic name etc : L-105 INN of investigational material : rifaximin Therapeutic category code : 619 Other antibiotic preparations (including mixed antibiotic preparations)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Subjects of completed the preceding study (L-105/2-A)

Exclusion criteria

Exclusion criteria: -Grade III or higher hepatic encephalopathy coma level (Coma Level Classification by Inuyama Symposium)

Design outcomes

Primary

Measure	Time frame
Efficacy and safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026